Administration of high-titer convalescent plasma containing neutralizing antibodies in the early stages of COVID-19 reduced viral load in a newly developed African green monkey model of COVID-19 better than low-titer CP or no treatment, according to a study posted before peer review on bioRxiv. Monkeys that received high-titer CP also had the lowest levels of inflammatory markers, blood clotting factors and lung damage, and while low-dose CP was less effective, it also reduced viral load and disease severity.
Convalescent plasma lowers COVID-19 severity in monkeys
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.